pentobarbital will lessen the level or result of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Keep away from coadministration. Strong or moderate CYP3A inducers may possibly decrease cobimetinib systemic exposure by >80% and lessen its efficacy. pent